Relay Therapeutics Stock Analysis
| RLAY Stock | USD 3.08 0.00 0.00% |
Relay Therapeutics is fairly valued with Real Value of 2.96 and Target Price of 21.45. The main objective of Relay Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Relay Therapeutics is worth, separate from its market price. There are two main types of Relay Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Relay Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Relay Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Relay Stock trading window is adjusted to America/New York timezone.
Relay |
Relay Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relay Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 2.36. The firm had not issued any dividends in recent years. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 320 people. To find out more about Relay Therapeutics contact MA MBA at 617 370 8837 or learn more at https://www.relaytx.com.Relay Therapeutics Investment Alerts
| Relay Therapeutics generated a negative expected return over the last 90 days | |
| Relay Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10.01 M. Net Loss for the year was (337.71 M) with loss before overhead, payroll, taxes, and interest of (305.43 M). | |
| Relay Therapeutics currently holds about 1.05 B in cash with (249.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 348 shares by Thomas Catinazzo of Relay Therapeutics at 7.7 subject to Rule 16b-3 |
Relay Therapeutics Upcoming and Recent Events
Earnings reports are used by Relay Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Relay Largest EPS Surprises
Earnings surprises can significantly impact Relay Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-02 | 2024-03-31 | -0.7 | -0.62 | 0.08 | 11 | ||
2022-08-04 | 2022-06-30 | -0.63 | -0.71 | -0.08 | 12 | ||
2023-05-04 | 2023-03-31 | -0.69 | -0.78 | -0.09 | 13 |
Relay Therapeutics Environmental, Social, and Governance (ESG) Scores
Relay Therapeutics' ESG score is a quantitative measure that evaluates Relay Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Relay Therapeutics' operations that may have significant financial implications and affect Relay Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Relay Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-12-31 | 3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 3 M | Goldman Sachs Group Inc | 2024-12-31 | 2.7 M | Eventide Asset Management, Llc | 2024-12-31 | 2.7 M | Millennium Management Llc | 2024-12-31 | 2.6 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 2.3 M | Finepoint Capital Lp | 2024-12-31 | 2.2 M | Boxer Capital Llc | 2024-09-30 | 1.8 M | Candriam Luxembourg S.c.a. | 2024-12-31 | 1.7 M | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 27.9 M | Vanguard Group Inc | 2024-12-31 | 15 M |
Relay Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 518.74 M.Relay Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (0.43) | (0.41) |
Management Efficiency
Relay Therapeutics has return on total asset (ROA) of (0.2811) % which means that it has lost $0.2811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4415) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2025. Return On Capital Employed is likely to drop to -0.48 in 2025. At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 29.3 M in 2025, whereas Total Assets are likely to drop slightly above 855.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.44 | 5.72 | |
| Tangible Book Value Per Share | 5.43 | 5.70 | |
| Enterprise Value Over EBITDA | (1.35) | (1.42) | |
| Price Book Value Ratio | 0.76 | 0.94 | |
| Enterprise Value Multiple | (1.35) | (1.42) | |
| Price Fair Value | 0.76 | 0.94 | |
| Enterprise Value | 512.8 M | 644.7 M |
Evaluating the management effectiveness of Relay Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Relay Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 24th of March, Relay Therapeutics holds the Variance of 26.51, coefficient of variation of (991.44), and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relay Therapeutics, as well as the relationship between them.Relay Therapeutics Price Movement Analysis
The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Relay Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Relay Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Relay Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relay Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relay Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relay Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relay Therapeutics Outstanding Bonds
Relay Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Relay Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Relay bonds can be classified according to their maturity, which is the date when Relay Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| RILIN 2875 12 JAN 32 Corp BondUS759470BB24 | View | |
| RILIN 3625 12 JAN 52 Corp BondUS759470BD89 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Relay Therapeutics Predictive Daily Indicators
Relay Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Relay Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0409 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 3.12 | |||
| Day Typical Price | 3.1 | |||
| Market Facilitation Index | 0.13 | |||
| Price Action Indicator | (0.04) | |||
| Relative Strength Index | 33.86 |
Relay Therapeutics Corporate Filings
| 20th of March 2025 Other Reports | ViewVerify | |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify | |
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Relay Therapeutics Forecast Models
Relay Therapeutics' time-series forecasting models are one of many Relay Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Relay Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Relay Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Relay Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Relay shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Relay Therapeutics. By using and applying Relay Stock analysis, traders can create a robust methodology for identifying Relay entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (33.75) | (35.43) | |
| Operating Profit Margin | (37.22) | (39.08) | |
| Net Loss | (33.75) | (35.43) | |
| Gross Profit Margin | 0.91 | 0.96 |
Current Relay Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Relay analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Relay analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 21.45 | Strong Buy | 13 | Odds |
Most Relay analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Relay stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Relay Therapeutics, talking to its executives and customers, or listening to Relay conference calls.
Relay Stock Analysis Indicators
Relay Therapeutics stock analysis indicators help investors evaluate how Relay Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Relay Therapeutics shares will generate the highest return on investment. By understating and applying Relay Therapeutics stock analysis, traders can identify Relay Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 146.4 M | |
| Common Stock Shares Outstanding | 142.9 M | |
| Total Stockholder Equity | 777.8 M | |
| Property Plant And Equipment Net | 57.7 M | |
| Cash And Short Term Investments | 781.3 M | |
| Cash | 124.3 M | |
| Accounts Payable | 14.1 M | |
| Net Debt | -75.8 M | |
| 50 Day M A | 3.9987 | |
| Total Current Liabilities | 50.7 M | |
| Other Operating Expenses | 382.5 M | |
| Non Current Assets Total | 62.1 M | |
| Non Currrent Assets Other | 2.1 M | |
| Stock Based Compensation | 94.1 M |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.